Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

To Lower Drug Prices, Look At Generic Industry Health Rather Than FDA, Woodcock Says

Sep 25 2018

• By Derrick Gingery

US dollars and pills

Related Content

FDA Contradicts AAM's Generic Market Consolidation Argument

Nov 21 2017

FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting

Jun 22 2017

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

Aug 05 2017

Code Cart Crisis: Anatomy Of An Emergency Drug Shortage

Jul 05 2017

Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

Aug 01 2018

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

May 04 2018

US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals

Sep 17 2018

US FDA's Generics Program Reaches 'Steady State' Milestone

Sep 07 2018

Could US Solve Drug Shortages With 'Heightened' M&A Scrutiny?

Sep 12 2018

PBMs Play Outsized Role … In Hearing On Health Sector Consolidation

Mar 06 2018

Additional Topics

United States Pricing Debate Generic Drugs FDA BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window